Printer Friendly

Factors Contributing to Long-Term Severe Visual Impairment in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.

1. Introduction

Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS-TEN overlap are considered a spectrum of severe immunologic dermatobullous conditions involving the skin and mucosal membranes and usually triggered by drugs or infections [1, 2]. Although rare, these diseases are very important because they have high mortality and morbidity rates with ocular involvement often being the most serious long-term sequala [2, 3]. Ocular manifestations of SJS/TEN can be classified according to the clinical stages: acute and chronic. Initial eye involvement is highly variable and can range from self-limited conjunctival hyperemia to extensive sloughing of the entire ocular surface epithelium, including the tarsal conjunctiva and eyelid margin, leading to symblepharon formation, foreshortening of the fornix, and corneal ulceration or perforation [5]. Acute ocular complications developed in 50-81% of patients hospitalized for SJS/TEN [4-6]. Late ocular features include cicatricial changes of the conjunctiva and eyelids, severe dry eye, and ocular surface failure. These chronic complications are multifactorial in origin. They may not solely result from severe ocular inflammation during the acute phase but may also be results of a vicious cycle of microscopic injury due to severe dry eye and eyelid pathologies which are the permanent damage after the acute stage and recurrent episodes of conjunctival inflammation unrelated to mechanical irritation which may occur at some period following the acute disease episode [7, 8]. Chronic ocular sequelae occurred in up to 35% of patients with blinding corneal damage representing the most severe long-term complication for survivors of SJS/TEN [9]. Not all patients with early involvement end up with significant loss of vision. Although ocular sequelae are related to ocular involvement severity in the acute phase [6], chronic ocular complications after SJS/TEN can present with a variable course that is not always the direct consequence of initial inflammatory process [7]. Also, some patients without acute ocular involvement developed late complications [10]. These findings might reflect that there may be other external or internal factors associated with long-term ocular surface failure and severe visual impairment besides an acute ocular involvement score. Female gender and the acute systemic involvement score have been found to be prognostic factors predicting chronic ocular complications and the final best-corrected visual acuity (BCVA) [11]. Additionally, few studies have investigated the effect of the causative agents on chronic ocular damage [11-13]. However, the relationship of the causative drugs and chronic ocular complications is still controversial. Therefore, the purpose of this study is to assess the correlation between patients' demographics and clinical characteristics including the inciting agents and the severity of long-term visual impairment from SJS-/TEN-related chronic ocular complications in Thai population.

2. Methods

A single-center, retrospective chart review was conducted at Ramathibodi Hospital, Bangkok, Thailand, between December 2004 and December 2014. This study was approved by the Ethics Committee of Mahidol University School of Medicine and carried out in accordance with the Declaration of Helsinki. Informed consents were obtained from all subjects prior to the study.

Patients with SJS or TEN or SJS-TEN overlap were identified from hospital's electronic patient medical records and from the Cornea and Refractive Surgery Service database. The eligible criteria were patients with a dermatological diagnosis of SJS or TEN or SJS-TEN overlap and a follow-up time of at least 1 year. The classification criteria of Bastuji-Garin et al. were used to describe SJS, TEN, and overlap syndrome [14]. SJS was defined as detachment below 10% of the body surface area (BSA) plus widespread erythematous or purpuric macules or flat atypical targets; overlap SJS-TEN, detachment between 10% and 30% of the BSA plus widespread purpuric macules or flat atypical targets; TEN with spots, detachment above 30% of the BSA plus widespread purpuric macules or flat atypical targets; and TEN without spots, detachment above 10% of the BSA with large epidermal sheets and without any purpuric macule or target. Patients who had a history of other ocular surface diseases or ocular surgeries were excluded from the study.

We retrospectively reviewed the medical records and collected all demographics and clinical data of each patient including the information about the pathogenesis of the SJS or TEN and the potential inciting agents. The causative drugs were identified by a dermatologist and a pharmacist based on the detailed medical history and drug information gathered for 4 weeks before the disease onset and risk estimates for each drug adapted from Roujeau et al. [15]. The main outcome measures were best spectacle-corrected visual acuity (BSCVA) and chronic ocular complications at the final follow-up. The final BSCVA was obtained prior to corneal or limbal transplantation. Adapted from the World Health Organization (WHO) [16], in this study, severe visual impairment was defined as BSCVA of less than 20/200 with corresponding chronic ocular complications. Chronic ocular surface complications were broadly categorized into 3 groups: corneal (superficial punctate keratopathy, epithelial defect, loss of the palisades of Vogt, conjunctivalization, neovascularization, opacification, and keratinization); conjunctival (hyperemia, symblepharon formation); and eyelid (trichiasis, mucocutaneous junction involvement, meibomian gland involvement, and punctal damage) complications, according to the grading system for the evaluation of chronic ocular manifestations in patients with SJS established by Sotozono et al. [17]. The worse eye of each patient was chosen for statistical analysis.

Statistical analyses were performed with the statistical software package STATA version 14.1 (StataCorp, College Station, Texas, USA). Mean and standard deviation (SD) or median and range were used to describe continuous data. Frequency and percentage were used to describe categorical data. The chi-square test (or Fisher exact test) and t-test (or Mann-Whitney test) were used to compare patient demographics and the effects of causative agents on long-term visual outcomes. Univariate and multivariate logistic regression analyses were used to evaluate prognostic factors related to long-term severe visual impairment (BSCVA < 20/200). Multivariate logistic regression analysis was performed with variables whose P value was less than 0.1 in univariate analysis. The relationship between chronic ocular complications and severity of visual impairment was analyzed by the same methodology. Odds ratio (OR) with 95% confidence interval (CI) was reported. Statistical significance was considered at P < 0.05.

3. Results

Over a 10-year period, 89 patients with SJS/TEN were recruited into the study. There were 55 (61.80%) females and 34 (38.20%) males. The mean age at the first visit was 41.58 [+ or -] 19.17 years (range, 1 to 79 years). Sixty-five patients (73.03%) were classified as SJS, 15 patients (16.85%) as TEN, and 9 patients (10.11%) as SJS-TEN overlap. Thirty-three patients (43.82%) had been referred from local hospitals. Of the 89 patients, 67 patients (75.28%) presented with ocular involvement in the acute phase. Twenty-three patients (25.84%) recovered without significant long-term sequelae, and 44 patients (49.44%) developed chronic ocular complications. Severe visual impairment was found in 23 patients (25.84%). The median follow-up time was 6.4 years (range, 1 to 24.3 years). Fifty-one (57.30%) patients had underlying diseases, including hypertension (16 cases; 17.89%), human immunodeficiency virus (HIV) infection (13 cases; 19.7%), diabetes mellitus (DM) (11 cases; 12.36%), collagen vascular diseases (10 cases; 11.23%), dyslipidemia (5 cases; 5.62%), chronic kidney disease (5 cases; 5.62%), and liver disease (2 cases; 2.25%). Of the 10 patients with collagen vascular diseases, systemic lupus erythematous (SLE) was found in 7 cases (7.87%), mixed connective tissue disease (MCTD) in 2 cases (2.25%), and rheumatoid arthritis (RA) in 1 case (1.12%). Twelve out of 13 patients with HIV infection (92.86%) had a CD4 count less than 200 cells/[micro]l (mean, 120.54 [+ or -] 130.61; range, 5-496).

The inciting agents responsible for SJS/TEN are summarized in Table 1. Drugs were the leading cause of SJS/TEN (83 patients, 93.26%), followed by infection (3 patients, 3.37%), and unknown etiology (3 patients, 3.37%). There were 2 patients infected by herpes simplex virus and 1 patient infected by Mycoplasma pneumoniae. They presented with classic clinical signs and symptoms of infection with positive seroconversion without previous history of taking medications. Infection and unknown etiology in patients were grouped together as nonpharmaceutical triggers. Among all offending medications, antibiotics were the most common cause (47.19%), followed by anticonvulsants (25.84%), allopurinol (12.36%), and nonsteroidal anti-inflammatory drugs (NSAIDs) (10.11%). The frequent inciting antibiotics included penicillins (21.35%), sulfonamides (12.36%), tetracyclines (3.37%), and macrolides (3.37%). One offending medication was observed in 58 patients (64.04%), 2 possible offending medications in 22 patients (24.72%), and 3 possible offending medications in 3 patients (3.37%).

From the univariate analyses, there were no statistically significant associations between demographic variables such as sex, age, diagnosis, underlying diseases, and long-term visual outcomes except for the causative agents and HIV infection (Table 2). Regarding the causative agents, nonpharmaceutical triggers (infection and unknown etiology) and antibiotics were significantly correlated with long-term severe visual impairment with OR of 7.20 (95% CI, 1.1345.96; P = 0.037) and 4.32 (95% CI, 1.44-14.02; P = 0.015), respectively. HIV infection was negatively correlated with long-term severe visual impairment (OR, 0.16; 95% CI, 0.03-0.71; P = 0.021). However, multivariate analysis could not be performed because no long-term severe visual impairment occurred in patients with HIV infection.

Of the 44 patients with chronic ocular complications, 23 patients (52.27%) ended up with severe visual impairment. Three major ocular surface complications including corneal, conjunctival, and eyelid complications as well as lens status are demonstrated in Table 3. The most common chronic ocular complication was superficial punctate keratopathy (79.55%), followed by corneal opacification (72.73%), and corneal neovascularization (56.82%). Univariate analysis showed that corneal neovascularization, symblepharon, and corneal opacification were significantly related to severe visual impairment (P < 0.05). From the multivariate model, only corneal neovascularization was significantly associated with severe visual impairment (OR, 15.66; 95% CI, 3.0680.22; P = 0.001).

4. Discussion

It is well known that ocular involvement is very prevalent in SJS/TEN and can be severe and blinding. Nonetheless, because of the rarity of the disease, the small number of patients treated at any single center each year, the high mortality rate, and the rise of concern about acute ocular therapy to prevent late ocular complications, there have been limited studies focusing on the long-term ophthalmological sequelae of surviving patients [6-11, 18]. Although considerable advances have been made in recent years in the management of ocular manifestations of SJS/TEN in both acute and chronic stages of the disorder, some existing reports are contradictory, and delayed or inadequate treatments can result in irreversible ocular damage and loss of visual function [3]. Therefore, identification of predictive factors for subsequent ocular complications is necessary to improve both initial and further managements.

Our study demonstrated that in SJS/TEN patients, antibiotics were the most frequent inciting drug consistent with those seen in previous reports from other Asian countries [17, 18]. Causative agents and the underlying HIV infection were found to be the risk factors for severe visual impairment in the aftermath of the disease. The SJS/TEN patients induced by antibiotics alone and nonpharmaceutical triggers, including mycoplasma and herpes simplex infections or unidentified etiology, had 4.32 and 7.20 times greater risk of long-term poor visual outcomes, respectively. Meanwhile, anticonvulsants, allopurinol, NSAIDs, and other drugs did not show any statistically significant relationship to longterm severe visual impairment. These findings are similar to prior studies from Japan and Korea which reported that cephalosporin-related SJS/TEN exhibited relatively higher tendencies of experiencing severe acute ocular surface involvements, although not significant (0.05 < P < 0.07), and patients with SJS/TEN that were associated with other drugs such as carbamazepine, allopurinol, and quinolones were not likely to develop severe ocular surface involvements [19,20]. However, NSAIDs have previously been observed to be potentially associated with chronic complications in a specific genetic background [12, 13]. In addition, a recent study found that SJS/TEN patients taking acetaminophen showed a significantly higher rate of experiencing severe ocular surface involvements than those taking other common causative drugs such as carbamazepine, allopurinol, and quinolones and the patients taking antipyretic analgesics, including acetaminophen and/or NSAIDs, for the treatment of common cold showed a higher frequency of experiencing severe ocular surface involvements compared with those taking antipyretic analgesics for the treatment of other diseases. Those results suggest that not only antipyretic analgesics but also viral infections causing cold-like symptoms may play some important roles in the development of severe ocular surface involvements [19]. Although that study looked into the relation of causative drugs to acute but not chronic ocular involvement, their observations give us a crucial idea that perhaps antipyretic analgesics which might have been prescribed along with antibiotics may actually influence the development of chronic ocular complications as well. Nevertheless, in this study, the information about acetaminophen use was not mentioned in any medical records and the prevalence of NSAID use was only 10.11%. This might be due to differences in self-medication patterns between various populations or a lack of awareness about the possibility of antipyretic analgesics being a precipitating factor of SJS/TEN so that clinicians did not inquire whether these drugs were administered before the onset of SJS/TEN. Also, cold medicinerelated SJS/TEN patients with severe ocular complications have been found to be associated with certain types of HLA (HLA-A* 02:06 and HLA-A* 44:03) and/or IKZF1 [21]. Thus, the variation in genetic backgrounds, drug use behavior, and criteria for the identification of inciting agents between different studies could be the reasons for the diverse outcomes. Furthermore, as nonpharmaceutical triggers appeared to be correlated with long-term severe visual impairment, it should be emphasized that overlooked medications especially antipyretic analgesics, subclinical or unrecognized infections, or other unidentified external factors could be potential etiologies of SJS/TEN causing severe ocular involvements.

TEN and SJS are more common in acquired immunodeficiency syndrome (AIDS) patients. Consequent dry eye may also be further exacerbated by HIV-related lacrimal gland dysfunction [22]. However, it is interesting that none of our patients who had HIV infection developed long-term severe visual impairment. There was only one study in the literature investigating the effect of HIV infection on ocular involvements in SJS/TEN patients [23]. In that study, no statistically significant difference in the severity of chronic ocular complications was found between HIV-positive and HIV-negative patients [23]. In additional analysis in a subgroup of HIV-infected patients, there was no significant difference in severity scores by CD4 category [23]. Nevertheless, the study was conducted in a predominantly HIV-infected population (HIV-positive is 59.3% compared to 19.7% in our study), and intriguingly, most of their patients had low ocular severity scores and good Snellen visual acuities ranging from 20/20 to 20/60. Their results actually correspond to our finding that HIV infection might be a protective factor against poor visual outcomes in the long run. We hypothesized that the state of immunosuppression by blunting antigen-specific response in HIV-infected patients might be a key factor in preventing hyperresponsive innate immune storm that leads to severe ocular involvements in SJS/TEN patients. Moreover, 92.86% of our HIV-infected patients had a CD4 count less than 200 cells/[micro]l, and the only 1 patient with a CD4 count above 200 cells/[micro]l (496 cells/[micro]l) was being in the state of a rapid decline in CD4 level. These results support our hypothesis of immunosuppressive conditions potentially resulting in less severe ocular complications and favorable visual outcomes in HIV-infected patients. However, few case reports illustrated severe acute ocular complications from SJS in AIDS patients [24, 25]. In those 2 cases, the SJS-induced epithelial defects were complicated by superimposed corneal infections and eventually healed with a visual acuity of 20/60 in 1 case and blindness secondary to endophthalmitis in another case. Hence, opportunistic infections in patients with HIV disease might modify the SJS-/TEN-related ocular manifestations or make them worse, leading to severe visual loss.

Although approximately 50% of our patients developed chronic ocular complications which were greater than that of the earliest report [9], variable degrees of many types of ocular sequelae have been increasingly seen in later studies [6-8]. Our prevalence could then be underestimated, probably owing to little knowledge of chronic ocular complications of SJS/TEN in the past and the retrospective design of the study. The proportion of patients with severe visual impairment in the chronic phase was comparable with that of previous reports [10, 17, 26]. Corneal neovascularization was significantly associated with severe visual impairment similar to the prior study [17]. Nonetheless, corneal opacification was not included into the multivariate analysis because all patients with severe visual impairment presented with corneal opacity.

The limitations of this study included inherent shortcomings in any retrospective study, relatively small sample size, heterogeneous patient populations, and variable follow-up time. In addition, this study enrolled pediatric patients, in which the prognosis and the response for the treatment are significantly different from the adult group [27]. However, there were a very small number of pediatric patients in the current study. Another major drawback of this study is that acute ocular features and treatments in the acute phase were not included in its analysis. Also, antiviral drugs which are the common inciting agents associated with SJS/TEN among HIV populations were not studied in more details. These are all caused by incomplete information in medical records which could result in some confounding factors among the causative agents and the underlying diseases. Future multicenter, large-scale, prospective studies with genetic analysis are needed to clarify the natural history of SJS/TEN and risk factors associated with long-term poor visual prognosis.

5. Conclusion

In conclusion, SJS/TEN patients caused by nonpharmaceutical triggers or antibiotics appear to have an increased risk of developing long-term severe visual impairment from corneal neovascularization. HIV infection might be a protective factor against long-term poor visual outcomes. These results shed light on the critical role of particular inciting agents, baseline immune status, and possible other undiscovered factors contributing to the long-term visual outcomes in SJS/TEN. Thorough medical history taking and meticulous ocular examination are strongly recommended for all SJS/TEN patients to identify vulnerable and high-risk patients to develop serious ocular sequelae. Prompt ophthalmologist consultation and closely monitoring by corneal specialists are essential in order to prevent long-term severe visual impairment.


The abstract of the manuscript was presented in the Asia Cornea Society meeting 2016 in Korea. The funding organizations played no role in the design or conduct of this research.

Conflicts of Interest

The authors declare that there is no conflict of interests regarding the publication of this paper.

Authors' Contributions

Passara Jongkhajornpong and Kaevalin Lekhanont contributed in the study concept and design. Passara Jongkhajornpong and Silada Kanokrungsee contributed in the acquisition of the data. Passara Jongkhajornpong, Sukanya Siriyotha, and Kaevalin Lekhanont performed the data analysis and preparation of Tables 1-3. Passara Jongkhajornpong, Kaevalin Lekhanont, and Varintorn Chuckpaiwong wrote the main manuscript text. All the authors critically reviewed the manuscript.


The authors wish to thank Sranya Phaisawang from Keen English Consulting for editing the manuscript. This work was supported by the SCG Foundation.


[1] A. Auquier-Dunant, M. Mockenhaupt, L. Naldi et al., "Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study," Archives of Dermatology, vol. 138, no. 8, pp. 1019-1024, 2002.

[2] M. Mockenhaupt, "The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis," Expert Review of Clinical Immunology, vol. 7, no. 6, pp. 803-813, 2011.

[3] S. Kohanim, S. Palioura, H. N. Saeed et al., "Acute and chronic ophthalmic involvement in Stevens-Johnson syndrome/toxic epidermal necrolysis--a comprehensive review and guide to therapy. II. Ophthalmic disease," The Ocular Surface, vol. 14, no. 2, pp. 168-188, 2016.

[4] Y. S. Chang, F. C. Huang, S. H. Tseng, C. K. Hsu, C. L. Ho, and H. M. Sheu, "Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: acute ocular manifestations, causes, and management," Cornea, vol. 26, no. 2, pp. 123-129, 2007.

[5] W. J. Power, M. Ghoraishi, J. Merayo-Lloves, R. A. Neves, and C. S. Foster, "Analysis of the acute ophthalmic manifestations of the erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis disease spectrum," Ophthalmology, vol. 102, no. 11, pp. 1669-1676, 1995.

[6] J. S. Lopez-Garcia, L. Rivas Jara, C. I. Garcia-Lozano, E. Conesa, I. E. de Juan, and J. Murube del Castillo, "Ocular features and histopathologic changes during follow-up of toxic epidermal necrolysis," Ophthalmology, vol. 118, no. 2, pp. 265-271, 2011.

[7] M. V. De Rojas, J. K. Dart, and V. P. Saw, "The natural history of Stevens Johnson syndrome: patterns of chronic ocular disease and the role of systemic immunosuppressive therapy," The British Journal of Ophthalmology, vol. 91, no. 8, pp. 1048-1053, 2007.

[8] M. A. Di Pascuale, E. M. Espana, D. T. Liu et al., "Correlation of corneal complications with eyelid cicatricial pathologies in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis syndrome," Ophthalmology, vol. 112, no. 5, pp. 904-912, 2005.

[9] M. J. Arstikaitis, "Ocular aftermath of Stevens-Johnson syndrome," Archives of Ophthalmology, vol. 90, no. 5, pp. 376-379, 1973.

[10] J. Gueudry, J. C. Roujeau, M. Binaghi, G. Soubrane, and M. Muraine, "Risk factors for the development of ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis," Archives of Dermatology, vol. 145, no. 2, pp. 157-162, 2009.

[11] D. H. Kim, K. C. Yoon, K. Y. Seo et al., "The role of systemic immunomodulatory treatment and prognostic factors on chronic ocular complications in Stevens-Johnson syndrome," Ophthalmology, vol. 122, no. 2, pp. 254-264, 2015.

[12] M. Ueta, C. Sotozono, K. Tokunaga, T. Yabe, and S. Kinoshita, "Strong association between HLA-A*0206 and StevensJohnson syndrome in the Japanese," American Journal of Ophthalmology, vol. 143, no. 2, pp. 367-368, 2007.

[13] M. Ueta, C. Sotozono, M. Nakano et al., "Association between prostaglandin E receptor 3 polymorphisms and Stevens-Johnson syndrome identified by means of a genome-wide association study," The Journal of Allergy and Clinical Immunology, vol. 126, no. 6, pp. 1218-1225.e10, 2010.

[14] S. Bastuji-Garin, B. Rzany, R. S. Stern, N. H. Shear, L. Naldi, and J. C. Roujeau, "Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme," Archives of Dermatology, vol. 129, no. 1, pp. 92-96, 1993.

[15] J. C. Roujeau, J. P. Kelly, L. Naldi et al., "Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis," The New England Journal of Medicine, vol. 333, no. 24, pp. 1600-1607, 1995.

[16] World Health Organization, ICD Update and Revision Platform: Change the Definition of Blindness, 2017, Retrieved from of%20Blindness.pdf?ua=1.

[17] C. Sotozono, L. P. Ang, N. Koizumi et al., "New grading system for the evaluation of chronic ocular manifestations in patients with Stevens-Johnson syndrome," Ophthalmology, vol. 114, no. 7, pp. 1294-1302, 2007.

[18] L. W. Yip, B. Y. Thong, J. Lim et al., "Ocular manifestations and complications of Stevens-Johnson syndrome and toxic epidermal necrolysis: an Asian series," Allergy, vol. 62, no. 5, pp. 527-531, 2007.

[19] N. Kaniwa, M. Ueta, R. Nakamura et al., "Drugs causing severe ocular surface involvements in Japanese patients with Stevens-Johnson syndrome/toxic epidermal necrolysis," Allergology International, vol. 64, no. 4, pp. 379-381, 2015.

[20] H. S. Lee, M. Ueta, M. K. Kim et al., "Analysis of ocular manifestation and genetic association of allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in South Korea," Cornea, vol. 35, no. 2, pp. 199-204, 2016.

[21] M. Ueta, "Genetic predisposition to Stevens-Johnson syndrome with severe ocular surface complications," Cornea, vol. 34, Supplement 11, pp. S158-S165, 2015.

[22] R. Belfort Jr, M. de Smet, S. M. Whitcup et al., "Ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with AIDS," Cornea, vol. 10, no. 6, pp. 536-538, 1991.

[23] L. Van Zyl, H. Carrara, and K. Lecuona, "Prevalence of chronic ocular complications in Stevens-Johnson syndrome and toxic epidermal necrolysis," Middle East African Journal of Ophthalmology, vol. 21, no. 4, pp. 332-335, 2014.

[24] V. Jain, D. Shome, and S. Natarajan, "Nevirapine-induced Stevens-Johnson syndrome in an HIV patient," Cornea, vol. 27, no. 3, pp. 366-367, 2008.

[25] M. Schulze Schwering, P. Kayange, J. J. van Oosterhout, and M. S. Spitzer, "Severe eye complications from Stevens-Johnson syndrome in a human immunodeficiency virusinfected patient in Malawi," The American Journal of Tropical Medicine and Hygiene, vol. 89, no. 1, pp. 162-164, 2013.

[26] N. Sharma, S. A. Thenarasun, M. Kaur et al., "Adjuvant role of amniotic membrane transplantation in acute ocular Stevens-Johnson syndrome: a randomized control trial," Ophthalmology, vol. 123, no. 3, pp. 484-491, 2016.

[27] K. H. Kim, S. W. Park, M. K. Kim, and W. R. Wee, "Effect of age and early intervention with a systemic steroid, intravenous immunoglobulin or amniotic membrane transplantation on the ocular outcomes of patients with Stevens-Johnson syndrome," Korean Journal of Ophthalmology, vol. 27, no. 5, pp. 331-340, 2013.

Passara Jongkhajornpong, (1) Kaevalin Lekhanont, (1) Sukanya Siriyotha, (2) Silada Kanokrungsee, (3) and Varintorn Chuckpaiwong (1)

(1) Department of Ophthalmology, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

(2) Department of Clinical Epidemiology and Biostatistics, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

(3) Department of Dermatology, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

Correspondence should be addressed to Passara Jongkhajornpong;

Received 27 January 2017; Revised 22 February 2017; Accepted 27 February 2017; Published 26 March 2017

Academic Editor: Jesus Pintor
Table 1: Causative agents associated with SJS/TEN patients and
relative frequencies.

Inciting agents                   Number of   Percentage
                                  patients       (%)
                                  (N = 89)

Medications                          83         93.26
Single possible drug                 58         64.04
  Antibiotics                        25         28.09
    Penicillins                       8          8.99
    Sulfonamides                      8          8.99
    Tetracyclines                     2          2.25
    Quinolones                        1          1.12
    Macrolides                        1          1.12
    Other antibiotics                 5          5.62
  Anticonvulsants                    10         11.24
    Carbamazepine                     6          6.74
    Phenytoin                         3          3.37
    Phenobarbital                     1          1.12
  Allopurinol                        11         12.36
  NSAIDs                              4          4.49
  Antimalarials                       2          2.25
  Antivirals                          2          2.25
  Other drugs                         4          4.49
Multiple possible drugs *            25         28.09
  Multiple antibiotics                7          7.87
  Antibiotics + anticonvulsants       5          5.62
  Antibiotics + NSAIDs                2          2.25
  Antibiotics + antivirals            1          1.12
  Antibiotics + bromhexine            1          1.12
  Multiple nonantibiotics             9         10.11
Nonpharmaceutical triggers            6          6.74
  Infections                          3          3.37
    Mycoplasma                        1          1.12
    Herpes simplex                    2          2.25
  Unidentified                        3          3.37
Total                                89          100

* More than one possible drug was identified.

Table 2: Analysis of the correlation between demographics and
severe visual impairment in SJS/TEN patients (n = 89).

Variables                      Nonsevere visual    Severe visual
                               impairment (%)     impairment (%)
                               (n = 66, 74.16%)   (n = 23, 25.84%)

  Male                           25 (37.88)          9 (39.13)
  Female                          41 (62.12)         14 (60.87)
Age (years)
  <40                            28 (42.42)         13 (56.52)
  [greater than or                38 (57.58)         10 (43.48)
  equal to] 40
  Overlap/TEN                    19 (28.79)          5 (21.74)
  SJS                             47 (77.21)         18 (78.26)
Diabetes mellitus
  Yes                             9 (13.64)          2 (8.70)
  No                              57 (86.36)         21 (91.30)
Autoimmune diseases
  Yes                             7 (10.61)          3 (13.04)
  No                              59 (89.39)         20 (86.96)
HIV infection
  Yes                             13 (19.7)            0(0)
  No                              53 (80.30)          23 (100)
Causative agents
  Nonpharmaceutical triggers       3 (4.55)          3 (13.04)
  Antibiotics alone               20 (30.30)         12 (52.17)
  Antibiotics with others         7 (10.61)          3 (13.04)
  Nonantibiotics                  36 (54.55)         5 (21.74)

Variables                         OR (95% CI)      P value

  Male                         1.05 (0.40-2.79)     0.915
  Female                             1.00
Age (years)
  <40                          1.76 (0.68-4.60)     0.245
  [greater than or                   1.00
  equal to] 40
  Overlap/TEN                  0.68 (0.22-2.12)     0.512
  SJS                                1.00
Diabetes mellitus
  Yes                          0.60 (0.12-3.02)     0.539
  No                                 1.00
Autoimmune diseases
  Yes                          1.26 (0.30-5.36)     0.750
  No                                 1.00
HIV infection
  Yes                          0.16 (0.03-0.71)    0.021*
  No                                 1.00
Causative agents
  Nonpharmaceutical triggers   7.20 (1.13-45.96)   0.037*
  Antibiotics alone            4.32 (1.44-14.02)   0.015*
  Antibiotics with others      3.09 (0.59-15.98)    0.179
  Nonantibiotics                     1.00

* Statistical significance P < 0.05; HIV: human immunodeficiency

Table 3: Analysis of the correlation between ocular findings
and severe visual impairment in SJS/TEN patients with chronic ocular
complications (n = 44).

                             Nonsevere visual    Severe visual
Ocular findings                 impairment       impairment (%)
                             (%) n (%), n = 21   n (%), n = 23
Corneal complications
  Yes                           19 (90.48)        16 (69.57)
  No                             2 (9.52)          7 (30.43)
Corneal opacification
  Yes                           9 (42.86)          23 (100)
  No                            12 (57.14)            0(0)
Corneal neovascularization
  Yes                           5 (23.81)         20 (86.96)
  No                            16 (76.19)         3 (13.04)
Conjunctival complications
  Yes                           7 (33.33)         13 (56.52)
  No                            14 (66.67)         10 (43.48)
  Yes                           3 (14.29)         12 (52.17)
  No                            18 (85.71)         11 (47.83)
Eyelid complications
  Yes                           7 (33.33)          9 (39.13)
  No                            14 (66.67)         14 (60.87)
  Yes                           8 (38.10)          6 (26.09)
  No                            13 (61.90)         17 (73.91)
Lens status
Cataract                        4 (19.05)          4 (17.39)
No cataract                     17 (80.95)         19 (82.61)

                             Univariate analysis
Ocular findings
                                 OR (95% CI)       P value
Corneal complications
  Yes                         0.60 (0.12-3.02)      0.539
  No                                1.00
Corneal opacification
  Yes                         2.56 (1.18-5.52)     0.017*
  No                                1.00
Corneal neovascularization
  Yes                        21.33 (4.42-103.06)   <0.001"
  No                                1.00
Conjunctival complications
  Yes                         2.60 (0.76-8.86)      0.127
  No                                1.00
  Yes                         6.55 (1.50-28.49)    0.012*
  No                                1.00
Eyelid complications
  Yes                         1.29 (0.37-4.42)      0.690
  No                                1.00
  Yes                         1.74 (0.48-6.28)      0.395
  No                                1.00
Lens status
Cataract                      0.89 (0.58-2.15)      0.887
No cataract                         1.00

                             Multivariate analysis
Ocular findings
                                OR (95% CI)       P value
Corneal complications
Corneal opacification
Corneal neovascularization
  Yes                        15.66 (3.06-80.22)   0.001*
Conjunctival complications
  Yes                        2.756 (0.48-15.92)    0.257
Eyelid complications
Lens status
No cataract

* Statistical significance P < 0.05. ** Statistical
significance P < 0.01; MGD: meibomian gland dysfunction;
SPK: superficial punctate keratopathy.
COPYRIGHT 2017 Hindawi Limited
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Research Article
Author:Jongkhajornpong, Passara; Lekhanont, Kaevalin; Siriyotha, Sukanya; Kanokrungsee, Silada; Chuckpaiwon
Publication:Journal of Ophthalmology
Date:Jan 1, 2017
Previous Article:Assessment of Ocriplasmin Effects on the Vitreoretinal Compartment in Porcine and Human Model Systems.
Next Article:Inherited Retinal Degeneration: Genetics, Disease Characterization, and Outcome Measures.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters